Xcellon Biologics Launches XSpec™ to Streamline Bioconjugation Program Design
As the field of targeted therapeutics continues to evolve, developers face increasing complexity in designing bioconjugates that meet both scientific and manufacturing requirements. From antibody-drug conjugates (ADCs) and radioconjugates to imaging agents and next-generation targeted therapies, successful development requires careful coordination of multiple variables—from conjugation chemistry and linker architecture to payload selection, analytical characterization, and […]